Batra G, Lakic TG, Lindbäck J, et al. - Elevated levels of interleukin 6 (IL-6) were linked to an increased risk of major adverse cardiovascular events (MACE) in individuals with chronic coronary syndrome across all chronic kidney disease (CKD) strata. As a result, IL-6 and CKD stage may be useful in identifying patients with chronic coronary syndrome who require anti-inflammatory treatment.

• This STABILITY trial substudy involved 14,611 patients who had baseline IL-6 levels available.

• The median (interquartile range) age was 65 (59-71) years, with 2,700 (18.5%) of the population being female.

• MACE occurred in 1,459 people (10.0%) during the follow-up period.

• Higher levels of IL-6 were in continuous models independently linked to the risk of MACE in all CKD strata.

• Using predefined strata, researchers discovered that elevated IL-6 levels were associated with an increased risk of MACE in people with normal kidney function, mild CKD, and moderate to severe CKD.